Association of XPC Polymorphisms with Cutaneous Malignant Melanoma Risk: Evidence from a Meta-Analysis

Asadian, Fatemeh; Niktabar, Seyed Mohammadreza; Ghelmani, Yaser; Kargar, Shadi; Akbarian, Elahe; Emarati, Seyed Alireza; Sadeghizadeh-Yazdi, Jalal; Neamatzadeh, Hossein

doi:10.14712/18059694.2020.27

Acta Medica > Archive > 2020, Vol. 63 > Issue 3 > Association of XPC Polymorphisms with…

Acta Med. 2020, 63: 101-112

https://doi.org/10.14712/18059694.2020.27

Association of XPC Polymorphisms with Cutaneous Malignant Melanoma Risk: Evidence from a Meta-Analysis

Fatemeh Asadian^a, Seyed Mohammadreza Niktabar^b, Yaser Ghelmani^c, Shadi Kargar^b, Elahe Akbarian^d, Seyed Alireza Emarati^d, Jalal Sadeghizadeh-Yazdi^e, Hossein Neamatzadeh^f,g

^aDepartment of Medical Laboratory Sciences, School of Paramedical Science, Shiraz University of Medical Sciences, Shiraz, Iran
^bDepartment of Surgery, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
^cClinical Research Development Center of Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
^dChildren Growth Disorder Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
^eDepartment of Food Science and Technology, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
^fDepartment of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
^gMother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Received February 21, 2020
Accepted June 29, 2020

Background: A number of studies have reported that the xeroderma pigmentosum complementation group C (XPC) polymorphisms are associated with cutaneous malignant melanoma (CMM) susceptibility. But the results of those studies were inconsistent. Here, we performed a study to obtain a more conclusive result on the association of XPC polymorphisms with risk of CMM. Methods: The XPC Lys939Gln and Ala499Val polymorphisms were genotyped in 150 CMM cases and 150 controls by PCR-RFLP assay. Subsequently, all published relevant studies were identified through a comprehensive literature search in PubMed, Web of Science, and CNKI databases. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the strength of correlation. Results: There was no significant association between XPC Lys939Gln and Ala499Val polymorphisms and CMM risk in our population. A total of 15 case-control studies including ten studies with 5,990 cases and 7,697 controls on XPC Lys939Gln and five studies with 3,139 cases and 3,721 controls on XPC Ala499Val polymorphism were selected. Pooled data revealed that XPC Lys939Gln (C vs. A: OR = 1.108, 95% CI 1.008– 1.217; P = 0.033) and Ala499Val (C vs. A: OR = 0.918, 95% CI 0.850–0.992; p = 0.031; CC+CA vs. AA: OR = 0.904, 95% CI 0.819–0.997; p = 0.043) polymorphisms were significantly associated with an increased risk of CMM. Moreover, stratified analyses by ethnicity revealed that the XPC Ala499Val and Lys939Gln polymorphisms were significantly associated with risk of CMM in Caucasians and mixed populations, respectively. Conclusions: This meta-analysis result suggested that XPC Lys939Gln and Ala499Val polymorphisms were significantly associated with risk of CMM.